Auxilium Pharmaceuticals (Nasdaq: AUXL) reported earnings on May 10. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Auxilium Pharmaceuticals beat expectations on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP loss per share shrank.

Gross margins dropped, operating margins increased, net margins grew.

Revenue details
 Auxilium Pharmaceuticals recorded revenue of $73.6 million. The 12 analysts polled by S&P Capital IQ predicted revenue of $71.2 million on the same basis. GAAP reported sales were 26% higher than the prior-year quarter's $58.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.04. The 10 earnings estimates compiled by S&P Capital IQ averaged -$0.11 per share. GAAP EPS were -$0.04 for Q1 versus -$0.25 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 77.4%, 330 basis points worse than the prior-year quarter. Operating margin was -2.6%, 1,760 basis points better than the prior-year quarter. Net margin was -2.4%, 1,790 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $72.5 million. On the bottom line, the average EPS estimate is -$0.09.

Next year's average estimate for revenue is $298.2 million. The average EPS estimate is -$0.29.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 124 members out of 176 rating the stock outperform, and 52 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give Auxilium Pharmaceuticals a green thumbs-up, and 26 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.92.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Auxilium Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.